Paul Whitehurst’s Post

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/GsLeHp 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/dqZJEH #oncology #oncologyresearch #ProductCitation

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

What is a checkpoint inhibitor? In our new CEO spotlight series, Vlad Vitoc, MD, MBA, dives into this drug that helps the immune system attack cancer cells. Find out by watching the video clip below and stay tuned for more as Vlad brings you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

🚨 The Future of Oncology: Next-Gen ADCs are Here! 🧬 Antibody-drug conjugates (ADCs) are entering their golden age, revolutionising cancer treatment by combining targeted therapy with potent cytotoxic drugs. This $12B market is projected to hit $44B by 2029! 🚀 Highlights: 🔬 Advanced payload & linker tech is widening therapeutic windows. 💊 ZAI Lab, Sutro Biopharma, Inc., and ADC Therapeutics are leading innovation. 💡 Beyond cancer: ADCs could tackle autoimmune diseases in the future! #Oncology #ADCTherapeutics #Biotech #CancerCare #Innovation

Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. 🧬✨ The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules

💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies

What is a checkpoint inhibitor? Watch as a dive into this immunotherapy agent, a type of drug that helps the immune system attack cancer cells. I'm Dr. Vlad Vitoc, Founder and CEO of MAIA Biotechnology, Inc. bringing you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Antibody-drug conjugates (ADCs) have emerged as a revolutionary approach to cancer treatment, enabling the targeted delivery of cytotoxic drugs to cancer cells while minimizing systemic toxicity. The global ADC market is witnessing remarkable growth, fueled by advancements in linker technologies, extensive research and development efforts, and the rising global incidence of cancer. In Taiwan, several companies are actively engaged in the development and manufacturing of ADCs, contributing significantly to the global oncology landscape. Download our FREE eBook: 𝐀 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐓𝐚𝐢𝐰𝐚𝐧'𝐬 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 for more insights. DOWNLOAD HERE: https://lnkd.in/gDEb2HSH #imagineyourimpact #antibodydrugconjugates #ADC2025